From evidence based on the use of specific receptor subtype antagonists, rt has generally been assumed that human uterine tissue contains only type 2 (AT 2 ) angiotensin II (All) receptor subtype. Using a monoclonal antibody, 6313/G2, directed against a specific sequence in the extracellular domain of the type 1 All receptor (AT,), in immunocytochemical studies, we show here that fijf receptor is expressed in human endometrium. In particular, positive staining was seen in the endometrial glandular epithelium, and in the vascular endothelium, while the myometrium and endometrial stroma were negative. The most intense staining was observed during the late prolrferative phase and less in the luteal phase. The ligand binding assay, using [ 125 l]-angiotensin II, revealed high concentrations of All receptors both in the endometrium and in the myometrium. Competition studies using losartan (AT, specific) and CGP42112B (AT 2 specific) showed that both AT-! and AT 2 receptor subtypes were present in the endometrium, though only the AT 2 receptor subtype was detected in the myometrium. Immunoblotting confirmed that the antibody 6313/G2 detected a single protein with a molecular weight of ~60 kDa. These data clearly demonstrate the presence of endometrial ATi receptors whose expression appears to be under hormonal control.
Introduction
The presence of angiotensin II (AD) receptors in the uterus has been well documented in rat (Lin and Goodfriend, 1970; Rouzaire-Dubois et al, 1975; Schirar et al, 1980) , dog (Capponi and Cart, 1979) , rabbit (Schirar et al, 1980) , monkey (Petersen et al, 1985) and human (Whitebread et ai, 1989) .
Although both type 1 (AT,) and type 2 (AT 2 ) receptor subtypes were demonstrated in the rat uterus (Whitebread et al., 1989; Dudley et al., 1990) , early reports suggested that only type 2 (AT2) AH receptors were found in the human uterus, and the AT, subtype was not (Whitebread et al, 1989) . However, this concept has recently been challenged, with the demonstration both of AT, receptor and of its mRNA in the human endometrium by using autoradiography and in-situ hybridization (Ahmed et al, 1995) .
Using ligand binding assays, immunocytochemistry and immunoblotting with a monoclonal antibody to the AT| receptor (Barker et al, 1993) , we provide further evidence for the expression of AT! receptors in the human uterus.
Materials and methods

Patients and tissue collection
Tissue samples were obtained from 18 women, aged 33-48, undergoing sterilization (n = 5) or hysterectomy (n = 13) for fibroid uterus or menorrhagia, after obtaining informed consent and local ethical committee approval. None of the patients were on © European Society for Human Reproduction and Embryology hormonal therapy or oral contraceptives. Immediately before the operation, a venous blood sample was taken for follicle stimulating hormone (FSH), luteinizing hormone (LH), oestradiol and progesterone measurements to determine the stage of the ovarian cycle. This was confirmed by histological examination of the endometrium using the criteria described by Noyes et al. (1950) . In a subgroup of normal, ovulatory women with proven fertility (n = 5), the menstrual cycle was dated by detection of LH surge in a daily specimen of blood and/or early morning urine and endometrial biopsies were taken at the time of tubal sterilization. All diese patients had regular menstrual cycles of 27-30 days and had at least one prior successful pregnancy within the last 5 years. These samples were used to study cyclical variation of AT[ receptor expression.
After removal, the uterine cavity was cut open and endometrial curettings and pieces of myometrium (0.5-2 g) were obtained. Care was taken to prevent contamination between the endometrial and myometriaJ samples. The tissue samples were immediately placed in ice-cold minimal essential medium with Earle's salts and L-glutamine (MEM-Earle's, Gibco, Paisley, UK) supplemented with heparin (CP Pharmaceuticals, Wrexam, UK) 1.8 IU/ml, streptomycin (Evans Medical, Surrey, UK) 50 Ug/ml, penicillin (Glaxo Laboratories, Middlesex, UK) 100 IU/ml and HEPES (Gibco) 10 mM. All visible evidence of blood was removed by washing the tissue in this medium. The tissue was then snap frozen in liquid nitrogen or fixed in 3.7% formal saline.
Immunoperoxidase staining of ATf receptors
Paraffin embedded sections (4 |im) were dewaxed in xylene and then immersed in absolute alcohol for 2 min. Sections were incubated in methanol containing 3% H 2 O2 for 15 min to block endogenous peroxidase activity and washed first in tap water for 10 min and then in distilled water for 5 min. Slides were then immersed in 10 mM citrate buffer (pH 6.0), covered with cling film and microwaved to boil at 100°C for 10 min at 630 W (H2500 BioRad, Watford, Herts, UK). They were left to stand for 10 min in hot buffer, washed in tap water for 10 min and then transferred into Tris-buffered saline (TBS; 50 mM Tris, 150 mM NaCl, pH 7.6). Non-specific sites were blocked by normal rabbit serum (Dako Ltd., High Wycombe, Bucks, UK) 1:5 dilution in TBS for 20 min. After incubation with 6313/G2 antibody (60 min) followed by washing for 5 min in TBS, the sections were incubated with biotinylated rabbit anti-mouse immunoglobulins (Dako) 1:400 dilution in TBS for 30 min. Excess antibody was removed as above and streptavidin-biotin complex (Dako) was applied according to the manufacturer's instructions.
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After a 30 min incubation the slides were washed in TBS for 5 min. 3,3'-Diaminobenzidine tetrahydrochloride (DAB; Sigma Chemical Co. Ltd., Poole, Dorset, UK) was used for visualization. The slides were then counterstained with Gill's haematoxylin (Sigma) for 2 min, washed in tap water for 5 min, differentiated briefly in acid alcohol, re-washed in water, dehydrated in industrial methylated spirit (BDH Ltd, Middlesex.UK), cleared with xylene and mounted with Canada balsam (BDH). Human adrenal tissue was used as positive control and primary antibody was substituted with non-specific mouse immunoglobulin for negative controls.
Tissue preparation for All binding assay, electrophoresis and immunoblotting
Tissue samples were minced on ice and homogenized in ice cold Tris-HCl buffer (50 mM containing EDTA 300 Hg/rnl, aprotinin 1 u.g/ml, soybean trypsin inhibitor 1 ug/ml and phenylmethylsulphonyl fluoride 1 ng/ml, pH 7.4), using a Polytron (Kinematica AG, LittauLuzern, Switzerland) homogenizer (2 X 15 s). The homogenates were centrifuged (800 g for 10 min at 4°C) and the resultant supematants were recentrifuged at 100 000 g for 60 min at 4°C. The paniculate fraction was resuspended in Tris-HCl buffer containing 100 mM NaCl, 6 mM MgCl 2 , 0.1% bovine serum albumin (BSA) and protease inhibitors. Protein content of the membrane suspension was determined according to the method of Lowry et al. (1951) using BSA as standard.
Ligand binding assay
Aliquots of membrane suspension containing 150 |tg protein were incubated with 0.1 nM [
125 I]-angiotensin II ( 5 Ile; 2000 Ci/mmol; Amersham International pic, Amersham, UK) in the presence of increasing concentrations of cold angiotensin II (Sigma) in 150 |il Tris-HCl buffer 50 mM, for 1 h at room temperature. Tubes were then placed on ice and 800 nl of ice-cold buffer was added. Bound and free radioactivity were separated by centrifugation at 10 000 g for 5 min at 4°C. After discarding the supernatant this step was repeated, and the radioactivity in the pellets was then counted by a Wallac 1410 gamma counter (LKB, Bromma, Sweden). The equilibrium constant (Kj) and concentration of receptor sites (Bmax) were determined by the method of Scatchard (1949) .
To determine the All receptor subtype, parallel incubations were carried out in the presence of varying concentrations of unlabelled angiotensin II (Sigma) the specific AT! antagonist Losartan (Du Pont Co. Delaware, USA) or the AT 2 antagonist CGP42112B (Ciba-Geigy, Basel, Switzerland).
Immunoblotting
Membrane suspensions containing 300 |ig protein were centrifuged at 10 000 g for 10 min at 4°C and the pellets were resuspended in 50 nl 0.5% Triton X-100 (Sigma) in Tris-HCl 50 mM. Sample buffer (50 |il, 62.5 mM Tris-HCl, 20% glycerol, 2% sodium dodecyl sulphate, 5% pVmercaptoethanol, pH 6.8) was added after 30 min. After boiling for 5 min samples were loaded on to 7.5% (2.67% crosslinking monomer concentration) sodium dodecyl sulphate-polyacrylamide gels (SDS-PAGE) (Laemmli, 1970) , running at 200 V for ~4 h. Separated proteins were then electrotransferred to Hybond-Enhanced ChemiLuminescence (ECL) nitrocellulose membranes (Amersham International) in buffer containing 25 mM Tris, 192 mM glycine and 20% (v/v) methanol overnight at 4°C, at 40 mA constant current. The membrane was washed in PBS containing 0.1% (v/v) Tween 20 (PBS-T; Sigma) and incubated for 1 h at room temperature with 10% (w/v) dried milk in PBS as a blocking reagent. After washing with PBS-T twice for 10 min the membrane was incubated with 6313/G2 antibody (1:20 dilution) at room temperature for 1 h. The membrane was washed with PBS-T as before and incubated with horseradish peroxidase linked sheep anti-mouse immunoglobulin (Amersham International) 1:5000 dilution for 1 h at room temperature. After a further wash in PBS-T, proteins were visualized using ECL by incubating the membrane for 1 min at room temperature with ECL-Westem blotting detection reagents (Amersham International) and exposing the membrane to Hyperfilm-ECL (Amersham International) for 2-3 min.
Results
Immunocytochemistry
Positive staining for the AT| receptor subtype was detected in the endometrial glandular epithelium and vascular endothelium. Myometrium and endometrial stroma were negative ( Figure  1A) . Intensity of the staining gradually increased as the cycle advanced from early proliferative phase to late proliferative phase ( Figure 1B,C) . The strongest staining was observed in the late proliferative phase endometrial samples ( Figure 1C ). There was less intense staining in luteal phase samples ( Figure 1D ,E).
Ligand binding assay and immunoblotting
Ligand binding assay for total All receptor (both AT| and AT 2 subtypes) content revealed high concentrations of All receptors in both the endometrium and myometrium (Figure 2 ). Although the myometrial receptor concentrations were higher than the corresponding endometrial values, this difference did not reach statistical significance (P >0.05, Mann-Whitney latest). Dissociation constants for All binding in the endometrium and myometrium were 29.4 ± 21.1 and 11.0 ± 2.5 nM respectively. Typical Scatchard plots from myometrial and endometrial samples are shown in Figure 3 .
Displacement studies using losartan and CGP421I2B showed that both AT] and AT2 receptor subtypes were present in the endometrium ( Figure 4A,C) . Approximately 25% of the total binding could be displaced by losartan, while 75% of the binding was displaced with CGP421I2B. Losartan showed no displacement in the myometrial samples and almost all binding could be displaced with CGP42112B ( Figure 4B,C) , confirming the presence of only AT 2 receptors in myometrium.
Immunoblotting using the antibody 6313/G2 detected a single band with a molecular weight of ~60 kDa ( Figure 5 ).
Discussion
The presence of a local renin-angiotensin system (RAS) in the uterus has been well documented (Squires and Kennedy, 1992) . Prorenin, renin, angiotensin and angiotensin receptors have been demonstrated in several studies (Symonds et al., 1968; Ferris et al, 1967; Warren et al, 1982; Dzau et al, 1987; Whitebread et al, 1989; Ahmed et al, 1995) . Until recently it was thought that only AT 2 receptors were expressed in the human uterus (Whitebread et al, 1989) . However, using in-situ hybridization, Ahmed et al. (1995) recently demonstrated the expression of AT) receptor mRNA in human endometrium. In addition, using the autoradiography technique they showed that both the AT] and AT 2 receptor concentration varied cyclically, the concentrations were highest in the early luteal phase and declined in the late secretory phase to mid proliferative phase values.
Using different methods, our results confirm that AT) as well as AT 2 receptors are expressed in human uterus. In particular, immunostaining with antibody 6313/G2 shows a strong reaction in the epithelial cells lining endometrial glands (Figure 1 ). This antibody is highly specific for the AT] receptor; it reacts positively to membrane components from COS-7 cells transfected with AT] cDNA, but not to those from untransfected cells. Furthermore, it recognizes only a single band in a wide range of tissues known to express AT[ receptors (Barker et al., 1993) . Using immunoblotting in the present experiments, the antibody detected 60 kDa protein, similar to that seen in other target tissues ( Figure 5 ).
It has previously been shown in the rat that expression of uterine All receptors is regulated by ovarian steroids, since administration of oestrogens increases receptor concentration whereas ovariectomy and progesterone decrease it (Schirar et al., 1980) . Cyclic variation in All receptor concentration also parallels hormonal changes (Schirar et al., 1980) . In our experiments, using human tissue, immunocytochemistry suggests that a similar control mechanism may be responsible for the AT] receptor expression in the endometrium, since the degree of staining increased during the proliferative phase and decreased during the luteal phase (Figure 1 ). These changes reflect those seen in Fallopian tube mucosa (Saridogan et al. 1996) and are consistent with a hormonal control mechanism. The peak receptor value seems to occur in the periovulatory phase. The minor discrepancy in the timing of the peak receptor value between our study and the study by Ahmed et al. (1995) can be explained by the difficulty in distinguishing the effects of hormonal changes in the early luteal phase when high oestrogen and low progesterone concentrations persist.
In ligand binding assays, separate myometrial and endometrial samples showed that only endometrial samples contained AT, receptor subtype, as demonstrated by displacement of [ l25 I]-angiotensin binding with losartan (Figure 4 ), though the AT 2 (CGP42112B displaceable) binding was nevertheless present in greater abundance (Figure 4) . However, no [
I25 I]-angiotensin II binding was displaceable in the myometrial samples, confirming the absence of AT| receptor subtype in this tissue. These findings thus reflect those found by immunoperoxidase staining and immunoblotting (Figures 1  and 5 ). These observations may also explain why Whitebread et al. (1989) failed to demonstrate AT| receptor expression in human uterus. In their study, the precise description of the tissue used for the binding assay was not given and it was not clear whether or not the endometrium was included. It is possible that only the myometrial samples were used or the binding assay was not sensitive enough to detect low concentrations of the AT, receptor subtype. Another report from the same group clarified that the myometrium had only AT 2 receptors (Criscione et al, 1993) .
The Brou values for the myometrium were lower in this study than previously reported values (Whitebread et al., 1989; Cox et al., 1996) . However, they were higher than the receptor concentrations reported by Ahmed et al. (1995) and similar to those reported by Schirar et al. (1980) in the rat uterus. There are clear differences between the reported values for the same tissue in the literature and these may reflect methodological 1 60 KDa- Figure 5 . ImmunoDiomng using ine 'aninxxfy DJ1J/UZ on samples from myometrium (1) and endometrium (2). Bovine adrenal membrane preparation (3) was used as positive control.
differences, or changes in receptor characteristics associated with changes in physiological status. In addition, both the B^j and Kj values seem to show significant changes under different hormonal conditions, as reported previously (Cox et al., 1996) . This suggests that the binding characteristics of the receptor may also vary with the cycle. The slightly higher K^ value found in the present study may be a reflection of the phase of the cycle of the patients studied.
In animals, All seems to be involved in at least two processes in the uterus. The dose-dependent contraction of the rat uterus seems to be mediated through the AT) receptor, since it is inhibited by losartan while selective AT 2 antagonists have no effect Barnes et al., 1991) . The second known effect of angiotensin in the uterus is its involvement in the decidualization process (Squires and Kennedy, 1992) . Recent data from the AT 2 'knockout' mice suggests that this receptor subtype does not have any critical role in reproduction (Hein et al., 1995; Ichiki et al., 1995) . The finding that AT, receptor mRNA concentration is highest in the endometrial blood vessels and glands (Ahmed et al. 1995) strongly suggests that decidualization is also mediated through the AT, subtype. Ahmed et al. (1995) also postulated that AT, receptors may be involved in the regeneration of the endometrium after menstruation, acting both as an angiogenic and mitogenic mediator. Further functional studies using the specific subtype antagonists are needed to confirm these hypotheses.
Current data and our previous data on the presence of AT| receptors in human spermatozoa and Fallopian tube and the stimulatory action of All on human sperm motility and Fallopian tube ciliary activity (Vinson et al, 1995a; Saridogan et al., 1996) suggest that All may play an important role in gamete transport and implantation. Furthermore, since the use of antibody 6313/G2 has shown the widespread presence of the AT! receptor in epithelial cells generally (Vinson et al, 1995b) , it may emerge that the regulation of fluid transport mechanisms is an important aspect of tissue renin-angiotensin system function.
